Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riliprubart - Sanofi

Next Previous
X
Search
Drug Profile

Riliprubart - Sanofi

Alternative Names: BIVV-020; SAR-445088; TNT-020

Latest Information Update: 26 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator True North Therapeutics
  • Developer Bioverativ; Sanofi; Sanofi-Aventis Recherche & Developpement
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Idiopathic thrombocytopenic purpura; Renal transplant rejection
  • Discontinued Autoimmune haemolytic anaemia

Most Recent Events

  • 26 Aug 2024 Discontinued - Phase-I for Autoimmune haemolytic anaemia in USA, Canada, Spain, Norway, Germany, Italy, United Kingdom, Netherlands (IV) (Sanofi Pipeline, August 2024)
  • 26 Aug 2024 Discontinued - Phase-II for Autoimmune haemolytic anaemia (IV) (Sanofi Pipeline, August 2024)
  • 25 Jun 2024 Efficacy and adverse events data from a phase II trial in Chronic inflammatory demyelinating polyradiculoneuropathy released by Sanofi

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top